BMS protein degradation drug research turns to a startup to find molecular glues

Bristol Myers Squibb’s drug R&D includes targeted protein degradation, an approach that can require proteins that don’t normally interact to find a way to stick together. BMS is turning to startup A-Alpha Bio to discover “molecular glues” that can accomplish the task.

Leave a Comment

Your email address will not be published.